Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Radiopharmaceuticals have been utilized for men with advanced prostate cancer for
decades. Older agents, seldom used today, provided palliation for bone metastatic pain. In …

The favorable decay characteristics of 161Tb attracted the interest of clinicians in using this
novel radionuclide for radioligand therapy (RLT). 161Tb decays with a similar half-life to …

Prostate cancer remains the commonest cancer diagnosed in males and a leading cause of
cancer-related death. Men with metastatic castration-resistant prostate cancer (mCRPC) …

Simple Summary Prostate-specific membrane antigen-direct radioligand therapy is a novel
treatment for patients with castration-resistant prostate cancer. Yet, given the mode of action …

In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical
state has been proposed as an intermediary step along the natural history of cancer with few …

Simple Summary This review article details new precision oncology-based therapeutics
used to treat advanced prostate cancer. Metastatic castration-resistant prostate cancer …

Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually
increases in high-grade tumors, metastatic tumors, and tumors nonresponsive to androgen …

Combination models utilising treatments from two or more therapeutic classes are well
established in cancer care. In the new era of theranostic (theragnostic) medicine there is an …

Simple Summary Lutetium-177-PSMA—a radiopharmaceutical composed of a radionuclide
lutetium-177 and a PSMA-binding ligand—is a theranostic medicine for prostate cancer. In …